Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease which has become a public health concern. Since oxidative stress plays a crucial role in the pathogenesis of NAFLD, subsequent hematological disorders are expected. Therefore, antioxidant compounds such as quercetin could ameliorate the related side-effect of oxidative stress. The aim of the current study was to assess the effect of quercetin on hematological parameters in NAFLD patients. A randomized, double-blind, placebo-controlled trial was conducted as a pilot study. In this study 90 patients with NAFLD were supplemented with either a quercetin or a placebo capsule twice daily (500 mg) for 12 weeks. Blood sample was obtained for laboratory parameters at baseline and the end of week 12. End of trial values for red blood cell (RBC; p = 0.002), mean corpuscular hemoglobin concentration (p = 0.029), and mean platelet volume (p = 0.017), significantly increased and the levels of mean corpuscular volume (MCV; p = 0.023), RBC distribution width-coefficient of variation (p = 0.005), platelet distribution width (p = 0.015), and ferritin (p = 0.002) significantly decreased compared to the baseline in group receiving quercetin. Between group analysis revealed that RBC significantly increased (p = 0.025) but, mean corpuscular volume (p = 0.004), mean corpuscular hemoglobin (MCH; p = 0.002), and ferritin (p = 0.013) significantly decreased compared to placebo group. In this work quercetin showed significant effect on RBC, ferritin, MCV, and MCH in intervention group.

Antioxidant micronutrients in the extract of Persian shallot may rehabilitate liver damages caused by free radicals in diabetic rats.

Many people believe that opium has beneficial effects on lipid profile which results in reduced atherosclerosis. Opium contains several alkaloids and biological active components, which some of them are used for atherosclerosis treatment. The liver X receptor α (LXRα) is an important regulator of cholesterol and glucose homeostasis that belongs to the nuclear receptor superfamily. This study aimed to investigate the effects of opium on glucose, lipid profile and LXRα expression. Sixteen N-mary mice randomly were divided into two groups (control and addict), and were studied for one month. Serum lipid profile, Fasting blood sugar (FBS), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) were determined. Also LXR mRNA and protein levels were determined by Reverse Transcription PCR and western blotting. This study showed that opium significantly reduced total cholesterol (P < 0.05), While the difference in blood glucose, triglyceride (TG), High-density lipoprotein cholesterol (HDL-c), Low-density lipoprotein cholesterol(LDL-c) and Very low-density lipoprotein cholesterol(VLDL-c), as well as AST and ALT between addict and control groups were not significant. More importantly, LXR protein and mRNA levels significantly increased (P < 0.05) in intestine of addict group in comparison with control, while the change in LXR protein and mRNA in the liver were not significant compared with control. The results of this study showed that opium addiction reduced total cholesterol and increased LXR expression in intestine. Further researches need to determine effective components.

No abstract

No abstract

Background: Recently, iron oxide nanoparticles have attracted attention in various diagnosis and treatment fields. The aim of the present study was to investigate the cytotoxicity of various concentrations and incubation times of dextran-coated iron oxide nanoparticles (DIONPs) on HeLa and MCF-7 cancerous cell lines.

Aflatoxin M1 is a major carcinogenic compound that may be existed in dairy products. The aim of this study was to determine the occurrence of AFM1 in traditional yoghurt samples in Guilan Province (Northern Iran). Ninety samples of traditional yoghurts were collected during summer and autumn 2014. Enzyme linked Immunosorbentassay (ELISA) which is a rapid and sensitive method was used to determine the presence and levels of AFM1. 100% of the yoghurt samples were contaminated with 5 and 83 ng/kg of AFM1. In general, AFM1 in 20 samples (22.22%) were higher than the maximum tolerance limit (50 ng/kg) accepted by the European Union. It was therefore concluded that, high occurrence of AFM1 in yoghurt is a serious risk for public health.

Purpose Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease which has become a public health concern, whose growing prevalence has been reported as around 33.9% in Iran. As oxidative stress plays a crucial role in the pathogenesis of NAFLD, antioxidant compounds such as quercetin could ameliorate the side effect of oxidative stress. The aim of the current study was to assess the effect of quercetin on lipid profile, liver enzymes and inflammatory indices in NAFLD patients. Design/methodology/approach In a randomized, double-blind, placebo-controlled trial conducted as a pilot study, 90 patients with NAFLD were supplemented with either a quercetin or a placebo capsule twice daily (500 mg) for 12 weeks. Both groups were advised to follow an energy-balanced diet with physical activity recommendations. Blood sample was obtained for laboratory parameters at baseline and the end of week 12. Findings At the end of the follow-up, quercetin group had significantly greater reduction in anthropometric parameters, cholesterol (−15 ± (−41, 0.00) in Q group versus −1± (−8, 2) in control group, p = 0.004), TG (−56.7 ± 22.7) in Q group versus −13.4 ± 27.7 in control group, p = 0.04), and tumor necrosis factor-α (TNF-α) (−49.5 ± (−99, 21) in Q group versus −5 ± (−21, 0.30) in the control group, p < 0.0001) compared to the control group. However, changes in fatty liver grade, liver enzymes, as well as high density lipoprotein-cholesterol and high-sensitivity C-reactive protein were not significantly different between the two groups. Originality/value To the best of the authors’ knowledge, this was the first study which assessed the effect of quercetin supplementation on liver enzymes, lipid profile and inflammatory indices of NAFLD patients as a double-blind placebo-controlled pilot study.